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Metformin (1,1-dimethylbiguanide) is a biguanide primarily used for the management of non–insu-
lin-dependent diabetes mellitus in humans and is the 
recommended first-line treatment following diagno-
sis.1 Metformin does not appear to affect pancreatic 
beta cell production of insulin, but to be effective, it 
requires the presence of circulating insulin.2,3 Metfor-
min reduces blood glucose concentration by enhanc-
ing muscle cell sensitivity to insulin and therefore 
increases muscle glucose metabolism.3–7 Metformin 
also decreases hepatic gluconeogenesis and glycoge-
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OBJECTIVE
To investigate the pharmacokinetics of metformin hydrochloride in healthy 
dogs after IV and oral bolus administrations and determine the oral dose of 
metformin that yields serum concentrations equivalent to those thought to 
be effective in humans.
ANIMALS
7 healthy adult mixed-breed dogs.
PROCEDURES
Each dog was given a single dose of metformin IV (mean ± SD dose, 24.77 
± 0.60 mg/kg) or PO (mean dose, 19.14 ± 2.78 mg/kg) with a 1-week wash-
out period between treatments. For each treatment, blood samples were 
collected before and at intervals up to 72 hours after metformin adminis-
tration. Seventy-two hours after the crossover study, each dog was admin-
istered metformin (mean dose, 13.57 ± 0.55 mg/kg), PO, twice daily for 7 
days. Blood samples were taken before treatment initiation on day 0 and 
immediately before the morning drug administration on days 2, 4, 6, and 7. 
Serum metformin concentrations were determined by means of a validated 
flow injection analysis–tandem mass spectrometry method.
RESULTS
After IV or oral administration to the 7 dogs, there was high interindividual 
variability in mean serum metformin concentrations over time. Mean ± SD half-
life of metformin following IV administration was 20.4 ± 4.1 hours. The mean 
time to maximum serum concentration was 2.5 ± 0.4 hours. Mean systemic 
clearance and volume of distribution were 24.1 ± 7.8 mL/min/kg and 44.8 ± 23.5 
L/kg, respectively. The mean oral bioavailability was 31%.
CONCLUSIONS AND CLINICAL RELEVANCE
The study data indicated that the general disposition pattern and bioavail-
ability of metformin in dogs are similar to those reported for cats and 
humans. (Am J Vet Res 2017;78:1193–1199)
nolysis. The overall consequence of these actions is 
to lower blood glucose concentrations without caus-
ing hypoglycemia.
There is clinical evidence that humans receiving 
metformin for treatment of non–insulin-dependent 
diabetes mellitus have a reduced lifetime incidence of 
cancer.8,9 This finding has led to substantial research 
to better understand metformin’s activity, including 
attempts to define the precise molecular target of 
metformin. Metformin’s mechanism of action is not 
understood but appears to target the enzyme AMPK. 
Increased activity of AMPK enhances glucose uptake 
from the blood into muscles.8,10 The upstream regula-
tor of AMPK is a protein kinase known as liver kinase 
B1, which is a tumor suppressor. Furthermore, results 
of in vitro investigations11 suggest that metformin 
may inhibit the proliferation of MDR cell lines and 
decrease the expression of the MDR marker, MDR1 
(p-glycoprotein), leading to reversal of chemotherapy 
resistance. This may be related to decreased expres-
sion of the drug efflux transporters (eg, MDR1), given 
that these efflux transporters may be responsible for 
ABBREVIATIONS
AMPK Adenosine monophosphate–activated pro-
   tein kinase
AUC Area under the serum concentration–time  
   curve
FIA-MS/MS Flow injection analysis–tandem mass spec-
   trometry
GFR Glomerular filtration rate
MDR Multidrug resistance
OCT Organic cation transporter
Tmax Time to maximum serum concentration
Vd-area Volume of distribution
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reduced effectiveness of chemotherapy agents such 
as doxorubicin.11 A further possible explanation of 
the mechanism is related to the impact of metfor-
min on chronic inflammation. Adenosine monophos-
phate–activated protein kinase may have the capac-
ity to reduce inflammation, which is an important 
component of the development and progression of 
cancer.10
A dearth of information exists regarding the ideal 
therapeutic concentration of metformin in humans. 
Kajbaf et al12 performed a systematic review of the 
human medical literature and found reported thera-
peutic values ranged widely from 0.129 to 90 mg/L 
(with boundary values of 0 to 1,800 mg/L). Detailed 
assessment of the available data suggests that a serum 
metformin concentration of 2.5 mg/L is the likely up-
per limit of the therapeutic range, whereas a lower 
limit could not be determined.12
To the authors’ knowledge, complete reports of 
metformin pharmacokinetic or pharmacodynamic 
data from which to determine an appropriate dose 
regimen in dogs are lacking. A recent publication13 re-
ported the development and validation of a high-per-
formance liquid chromatography–tandem spectrom-
etry method for the simultaneous determination of 
plasma concentrations of metformin and pioglitazone 
(another orally administered anti-diabetic agent) in 6 
Beagles.
The use of metformin in other species has pro-
vided basic knowledge of the drug’s pharmacokinet-
ics. Metformin is excreted unchanged in urine in hu-
mans and cats.1,4,5,14 As such, normal kidney function 
is imperative for the excretion of this drug and to pre-
vent its accumulation. In humans, lactic acidosis is a 
rare life-threatening condition that has been linked 
to high circulating metformin concentrations and is 
often associated with renal dysfunction.4–6 In dogs, 
the adverse effects of metformin, of which vomiting 
is most common, have been documented only af-
ter accidental oral ingestion of large amounts of the 
drug; even at high doses, these adverse effects are 
minimal.14
Given the potential benefits of metformin indi-
cated by results of recent human studies,2,8,9,15 de-
termination of the pharmacokinetics of metformin 
in dogs will allow for further investigation into its 
potential use in cancer prevention and treatment for 
both companion animals and humans. The purpose 
of the study reported here was to investigate the 
pharmacokinetics of metformin in healthy dogs after 
IV and oral bolus administrations and determine the 
oral dose of metformin that yields serum concentra-




Metformin hydrochloridea (500 mg) was dis-
solved in 10 mL of saline (0.9% NaCl) solution and 
passed through a filter (pore diameter, 0.2 µm) for IV 
administration. For oral administration, metformin 
hydrochloride tabletsb (500 mg each) were used.
Dogs
Seven healthy adult mixed-breed dogs (2 sexu-
ally intact males, 2 neutered males, 1 sexually intact 
female, and 2 spayed females) between 2 and 3 years 
old and weighing between 25.7 and 29.2 kg (mean ± 
SD weight, 27.96 ± 1.21 kg) were used. Physical ex-
aminations and preliminary diagnostic tests includ-
ing a CBC, serum biochemical analysis, urinalysis, 
and blood lactate concentration assessment were 
performed before initiation and at termination of the 
study. All dogs were considered healthy at the time 
of the study. The dogs had been well adapted to their 
environment and were accustomed to being handled. 
They were housed at the Western College of Veter-
inary Medicine Animal Care Unit. The study had 2 
phases, was approved by the University of Saskatch-
ewan’s Animal Research Ethics Board, and adhered to 
the Canadian Council on Animal Care guidelines for 
humane animal use.
Experimental procedures
Phase 1 involved IV and oral administrations 
of a single dose of metformin in a crossover design 
study, with 2 experimental periods and an interven-
ing 1-week washout period. All dogs received each 
treatment, though not in the same order. One day 
prior to each experimental period, each dog was 
sedated with butorphanol tartrate (0.4 mg/kg) and 
dexmedetomidine (2.5 µg/kg) administered IV, and 
an indwelling jugular sampling catheterc was placed 
aseptically with a modified Seldinger technique. To 
maintain catheter patency, 2.0 mL of sterile heparin 
solution (1,000 U/mL) was injected into the catheter 
every 6 hours. The dogs were housed in the West-
ern College of Veterinary Medicine Animal Care Unit 
during data collection and received 30 minutes of ex-
ercise once daily throughout the experimental and 
washout periods and the interval between phases 1 
and 2.
Food was withheld from each dog for 16 hours 
before and 6 hours after the IV or oral dose admin-
istration. For the IV treatment, each dog was admin-
istered 23.4 to 25 mg of metformin/kg (mean ± SD 
dose, 24.77 ± 0.60 mg) IV over a period of 5 minutes. 
For the oral treatment, each dog was administered 
17.18 to 25.68 mg of metformin/kg (mean dose, 19.14 
± 2.78 mg). Serial blood samples for analysis were ob-
tained by removal of 2 mL of blood from the catheter, 
after initial removal of 2 mL to clear the catheter of 
heparin. After sample collection, 2 mL of sterile sa-
line solution was reinstilled to replace blood volume 
and heparin within the catheter. Following a 1-week 
washout period, dogs received treatment by the other 
route of administration. Blood samples (2 mL each) 
were collected into tubes containing no anticoagu-
lant before (0 hours) and at 0.33, 0.57, 1, 1.33, 1.67, 
2, 2.5, 3, 4, 5, 6, 7, 8, 10, 12, 15, 18, 24, 30, 36, 48, 
and 72 hours after metformin administration for drug 
 AJVR • Vol 78 • No. 10 • October 2017 1195
analysis. Portions of the blood samples were used 
for immediate analysis of blood lactate and glucose 
concentrations (by use of a bench top lactometer and 
glucometer, respectively) at the 0-, 6-, 12-, 24-, 48-, 
and 72-hour time points. Blood samples were then al-
lowed to clot for 45 minutes before centrifugationd 
for 10 minutes. The serum was transferred to 1.5-mL 
plastic microcentrifuge tubes and stored at –80°C un-
til analysis of metformin concentrations by an FIA-
MS/MS method.16 The indwelling jugular sampling 
catheter was removed from each dog at the end of 
each experimental period. During phase 1, the dogs 
were constantly monitored for the first 3 hours fol-
lowing metformin administration, then hourly until 
24 hours, every 6 hours up to 48 hours, and 3 times a 
day until metformin treatment via the other route of 
administration or initiation of phase 2. The general 
demeanor of the dog was evaluated along with signs 
of nausea, evidence of vomiting or diarrhea, appetite, 
energy levels, urination habits, and any other behav-
ior deemed to be unusual for the dog. The dog’s rec-
tal temperature, heart rate, respiratory rate, and body 
weight were also assessed on a daily basis.
There was an interval of 72 hours between 
phases 1 and 2. Phase 2 consisted of twice-daily oral 
administration of metformin to each dog for 7 days. 
Each dog was administered 12.89 to 14.24 mg of met-
formin/kg (mean ± SD dose, 13.57 ± 0.55 mg) orally 
twice each day. The first dose was administered on 
day 0, and the last dose was administered on day 6. 
Blood samples (2 mL each) were collected for analy-
sis of serum drug and blood lactate concentrations 
before treatment initiation (baseline) and just before 
the morning drug administration on days 2, 4, and 
6; a final blood sample was collected for analysis at 
the time of the morning drug administration on day 
7, but dogs were not treated that day. Portions of the 
blood samples were used for immediate analysis of 
blood lactate concentration (by use of a benchtop 
lactometer). Blood samples were then allowed to clot 
for 45 minutes before centrifugation for 10 minutes. 
The serum was transferred to 1.5-mL plastic micro-
centrifuge tubes and stored at –80°C until analysis of 
metformin concentrations by an FIA-MS/MS method. 
During phase 2, the dogs were monitored 3 times a 
day up to and including day 7. The general demeanor 
of the dog was evaluated along with signs of nau-
sea, evidence of vomiting or diarrhea, appetite, en-
ergy level, urination habits, and any other behavior 
deemed to be unusual for the dog. The dog’s rectal 
temperature, heart rate, respiratory rate, and body 
weight were also assessed on a daily basis.
Assessment of serum metformin  
concentrations
For each sample from either of the experimental 
phases, serum metformin concentration was deter-
mined by a previously validated FIA-MS/MS method.16 
Briefly, serum samples were thawed to room tem-
perature (approx 21°C) and gently mixed. A 170-µL 
volume of precipitation solution (acetonitrile contain-
ing 0.1% formic acid and 20 ng of metformin-d6 hy-
drochloride/mL) was added to 50 µL of each serum 
sample. The resulting mixture was vortexed for 30 
seconds and then centrifugede at 4°C for 10 minutes. 
The supernatant was then transferred to high-per-
formance liquid chromatography vials, and FIA-MS/
MS was performed.16 A 2-µL sample volume was used 
with a run time of 2 minutes. For 2 quality control 
concentrations, recovery was found to be 97.3% for 
12-ng/mL samples and 94.5% for 117-ng/mL samples. 
The standard curve was prepared from serial dilution 
of the stock solution to 7 standard working stock so-
lutions and subsequent addition of 10 µL of the work-
ing solution to 40 µL of pooled blank dog serum. A 
170-µL volume of precipitation solution was added to 
each standard sample and processed for FIA-MS/MS 
as described. The standard curve was constructed 
from peak-area ratios of metformin to internal stan-
dard plotted against the known metformin standard 
concentration. A linear regression analysis with 1/x 
weighting gave an R2 > 0.9966 in the range of 5 to 
2,340 ng/mL. The intra- and interday accuracy and 
precision of 3 metformin concentrations at the low 
end, middle, and high end of the standard curve 
range (n = 6 assessments/concentration on each of 
3 occasions) were within 15% deviation from the 
known concentrations. Quality control samples rep-
resenting concentrations on the low end, middle, and 
high end of the standard curve range were analyzed 
in duplicate and were used as acceptance criteria for 
a single analysis run. At a minimum, 4 of 6 quality 
control samples (allowing for 1 quality control sam-
ple within 2 of the 3 quality control concentrations 
to fail) had to be within 15% of the known concentra-
tion; otherwise, the analysis run was rejected.
Pharmacokinetic analysis
For each dog, pharmacokinetic parameters were 
estimated from serum metformin concentrations over 
time (determined in phase 1) by noncompartmental 
methods,f and final pharmacokinetic parameter es-
timates were expressed as mean ± SD. For noncom-
partmental analysis, the values of AUC from time 0 
extrapolated to infinity were calculated by the linear 
trapezoidal rule extrapolation method to obtain esti-
mates of systemic clearance and Vd-area. The log-linear 
terminal rate constant, k, was estimated as the termi-
nal slope of the natural logarithmic mean serum met-
formin concentration-versus-time profile following 
linear regression analysis; the half-life was estimated 
as the ratio 0.693/k. The maximum serum concentra-
tion and Tmax were determined from visual inspection 
of the serum metformin concentration following oral 
administration-versus-time profiles. Bioavailability 
(F) was calculated with an equation as follows:
F =
  AUCoral  X
 Doseiv
       Doseoral         AUCiv
where AUCoral is the estimated AUC from time 0 ex-
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trapolated to infinity following oral bolus administra-
tion of metformin, AUCiv is the estimated AUC from 
time 0 extrapolated to infinity following IV bolus 
administration of metformin, and Doseiv and Doseoral 
are the metformin doses administered by the IV and 
oral routes, respectively.
Results
All data are reported as mean ± SD. The mean 
serum metformin concentrations over time after IV 
and oral administration revealed extensive interindi-
vidual variation among the 7 mixed-breed dogs (Fig-
ure 1). The terminal linear phase rate constants for 
the natural logarithmic mean serum metformin con-
centration-versus-time profiles were similar follow-
ing IV (0.035 ± 0.007 hours−1) and oral (0.057 ± 0.015 
hours−1) bolus administrations. The IV administration 
data suggested a possible prolonged redistribution 
of metformin from peripheral tissue compartments, 
consistent with the long half-life (20.4 ± 4.1 hours) 
and large Vd-area (44.8 ± 23.5 L/kg; Table 1). The low 
systemic clearance (24.1 ± 7.8 mL/min/kg) and high 
Vd-area were also consistent with the long half-life. Fol-
lowing oral administration, metformin had a moder-
ately rapid absorption rate (Tmax, 2.5 ± 0.4 hours), but 
the extent of absorption was rather low (oral bioavail-
ability, approx 0.31). The mean serum concentration 
of metformin measured just prior to a dose adminis-
tration seemed to plateau by 144 hours (Figure 2), 
consistent with the drug’s prolonged half-life.
Two of the 7 dogs developed mild gastrointesti-
nal signs in 1 or both phases of the study. Both dogs 
had a slight decrease in appetite fol-
lowing administration of the IV bolus 
in phase 1, and 1 dog had a single epi-
sode of vomiting and diarrhea on day 2 
of phase 2. No adverse effects were ob-
served in any dog following adminis-
tration of the single oral bolus. Among 
the dogs, no episodes of hypoglycemia 
were identified during phase 1, and no 
evidence of lactic acidosis was docu-
mented during either phase.
Discussion
Metformin is an antihyperglyce-
mic agent used frequently in the man-
agement of non–insulin-dependent 
diabetes mellitus in humans.1 More 
recently, it has been evaluated for po-
tential antineoplastic activity on the 
basis of clinical evidence that patients 
receiving metformin for treatment of 
non–insulin-dependent diabetes mel-
litus have a reduced lifetime incidence 
of cancer.8,9 This has led to the ques-
tions of whether this finding could be 
applicable to companion animals and 
whether data from companion animals 
treated with metformin could be used 
to further understand use of this drug 
in humans. Because information re-
garding the pharmacokinetics and oral 
bioavailability of metformin in healthy 
dogs is lacking, the purpose of the 
present study was to determine those 
parameters. The total daily oral dose 
of metformin currently used in anti-
cancer clinical trials in humans ranges 
from 1,500 to 2,000 mg.
The pharmacokinetics of metfor-
min after oral administration in dogs 
in the present study was similar to the 
pharmacokinetics reported for cats 
and humans. Peak serum concentra-
tion of the drug after oral administra-
Figure 1—Mean + SD serum metformin concentrations over time following IV 
(A) and oral (B) administration of a bolus dose of metformin hydrochloride to 7 
mixed-breed dogs (phase 1) in a crossover experiment (interval of 1 week be-
tween treatments). Food was withheld from each dog for 16 hours before and 6 
hours after either dose administration. The mean dose of metformin administered 
IV was 24.77 ± 0.60 mg/kg; the mean dose of metformin administered orally was 
19.14 ± 2.78 mg/kg. For each treatment, blood samples were collected into tubes 
containing no anticoagulant before (0 hours) and at 0.33, 0.57, 1, 1.33, 1.67, 2, 2.5, 
3, 4, 5, 6, 7, 8, 10, 12, 15, 18, 24, 30, 36, 48, and 72 hours after metformin admin-
istration for drug analysis by FIA-MS/MS.
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tion was approximately 2.5 hours, compared with 1 
hour in cats4 and 3 hours in humans.1 Oral bioavail-
ability of metformin in dogs was 31%, which was 
similar to 48% reported for cats4 and 32% to 61% 
reported for humans.17 Although oral bioavailability 
studies are typically conducted in fasted humans or 
other animals from which food has been withheld, 
food influences the rate and extent of absorption 
depending on the formulation of metformin. Use of 
metformin as adjuvant treatment in cancer patients 
may warrant further evaluations of the effect of food 
on absorption kinetics of rapid-release or extended-
release formulations of metformin.
It is expected that metformin distribution to pe-
ripheral tissue compartments in dogs is similar to the 
distributions in other animals and humans. Chemi-
cally, metformin is a hydrophilic base, which at physi-
ologic pH exists as a cationic species.1 Therefore, pas-
sive diffusion through cell membranes is generally 
limited. Metformin is transported into cells by mem-
brane transport proteins, such as OCTs and plasma 
membrane monoamine transporters.1,2 Hence, the 
expression of transport proteins on different cell 
types will affect the bioactivity and the distribution 
characteristics of metformin. Plasma membrane 
monoamine transporters are thought to be the major 
transporters responsible for metformin uptake from 
the gastrointestinal tract, whereas OCT1 and OCT3 
are important transporters of metformin in the liver.1 
In humans, genetic variants of OCT1 and OCT3 exist, 
which lead to differences in the transport of metfor-
min into cells. Given that transporters are important 
in the absorption, distribution, and elimination of 
metformin, genetic variation may lead to a consider-
able difference in the response to metformin among 
individuals.1
Metformin is extensively excreted 
into the urine via glomerular filtration 
and tubular secretion with OCT2 and 
multidrug and toxin extrusion proteins 
appearing to have dominant roles.18–20 
A definitive reference range for GFR in 
dogs is not currently available because 
of GFR variations associated with age, 
breed, and concurrent disease. Previ-
ously published data obtained from 
dogs suggest that GFR ranges from 
3.05 to 4.85 mL/min/kg depending on 
the assessment method.21 The mean 
systemic clearance determined in the 
present study (24.1 ± 7.8 mL/min/kg) 
was considerably higher than the pro-
posed GFR, likely indicating that met-
formin is principally excreted by active 
tubular secretion. This was similar to 
what has been determined for humans, 
in whom renal clearance of metformin 
is approximately 5 times the creatinine 
clearance of metformin.17 However, in 
cats, the mean renal clearance of met-
formin was only 1.4 times the GFR, suggesting active 
tubular secretion is not as important in the renal ex-
cretion of metformin in cats4 as it is in humans and 
dogs.
Metformin is rapidly distributed but evidence in 
humans suggests that drug binding to plasma pro-
teins does not occur. This contributes to a high ap-
Table 1—Mean ± SD pharmacokinetic parameter estimates 
(determined by noncompartmental methods) for metformin 
following IV and oral administration of a bolus dose of met-
formin hydrochloride to 7 mixed-breed dogs in a crossover 
experiment (interval of 1 week between treatments).
 Route of administration
Parameter IV Oral
Cmax (ng/mL)  — 835.8 ± 308.3
Tmax (h) — 2.5 ± 0.4
ClS (mL/min/kg) 24.1 ± 7.8 —
Vd-area (L/kg) 44.8 ± 23.5 —
F (%) — 31 ± 12
T1/2 (h) 20.4 ± 4.1 12.6 ± 2.9
K (h–1) 0.035 ± 0.007 0.057 ± 0.015
AUC (ng•h/mL) 18,567 ± 4,892 4,687 ± 1,170
C0 (ng/mL) 13,499 ± 5,401 —
Vd-area/F — 0.076 ± 0.018
Weights of the dogs ranged from 25.7 to 29.2 kg. Food was with-
held from each dog for 16 hours before and 6 hours after either dose 
administration. The mean ± SD dose of metformin administered IV 
was 24.77 ± 0.60 mg/kg; the mean dose of metformin administered 
orally was 19.14 ± 2.78 mg/kg. After each treatment, blood samples 
were collected into tubes containing no anticoagulant before (0 hours) 
and at 0.33, 0.57, 1, 1.33, 1.67, 2, 2.5, 3, 4, 5, 6, 7, 8, 10, 12, 15, 18, 24, 
30, 36, 48, and 72 hours after metformin administration for analysis of 
serum drug concentrations by FIA-MS/MS.
— = Not applicable. C0 = Serum concentration at 0 hours. ClS = 
Systemic clearance. Cmax = Maximum serum concentration. F = Oral 
bioavailability. K = Terminal natural log-linear phase rate constant. T1/2 
= Half-life. 
Figure 2—Mean + SD serum metformin concentrations over time following 
twice-daily oral administration of metformin (phase 2) to the 7 dogs in Figure 
1. There was an interval of 72 hours between phases 1 and 2. The mean dose 
of metformin administered was 13.57 ± 0.55 mg/kg. The first dose was adminis-
tered on day 0, and the last dose was administered on day 6. Blood samples were 
collected for analysis of serum drug concentrations before treatment initiation 
(baseline) and just before the morning drug administration on days 2, 4, and 6; 
a final blood sample was collected for analysis at the time of the morning drug 
administration on day 7, but dogs were not treated that day.
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parent Vd-area. Because metformin is a small, charged 
molecule at physiologic pH, plasma protein binding 
of the drug is likely limited in dogs, but this should be 
confirmed in future evaluations of metformin in dogs. 
In humans, there is evidence of a slow association of 
the drug with RBCs.1 The peak concentration of met-
formin following administration of a single dose in 
humans is initially higher in plasma than in erythro-
cytes. However, the subsequent decrease in concen-
tration in erythrocytes is much slower than that in 
plasma.1 This perhaps explains the prolonged elimi-
nation half-life of metformin observed in humans (9 
to 19 hours) and dogs (20.4 hours), compared with 
that in cats (11.4 hours).4,17 Given the metformin half-
life in dogs determined in the present study, once-
daily dosing would be expected to provide adequate 
steady-state serum concentrations over time. Once-
daily dosing of metformin may also help to limit any 
gastrointestinal adverse effects.
One objective of the study of this report 
was to determine the oral dose of metformin 
that would yield serum concentrations similar 
to those thought to be effective in humans. One 
difficulty when trying to achieve this objective 
was that there is no clear definition of therapeu-
tic concentrations in humans.12 Many studies 
have solely used pharmacokinetic data to define 
therapeutic concentrations. However, such data 
may predominately evaluate the drug’s maximum 
concentration in the blood after a single dose 
as opposed to the steady-state concentrations 
achieved with a long-term dosing regimen.12 An-
other concern is that the amount of the drug at 
its site of action within the tissues may not be re-
f lected by the serum concentration. Through re-
view of the human medical literature, evaluation 
of trough serum concentrations associated with 
well-tolerated doses has suggested a likely upper 
limit of the therapeutic range of 2.5 mg/L.1,12
In the present study, metformin appeared to be 
well tolerated, with development of no adverse ef-
fects in most dogs or only mild transient gastrointes-
tinal signs. No episodes of hypoglycemia or evidence 
of lactic acidosis were documented. However, there 
have been reports of idiosyncratic, hyperlactemic re-
sponses to metformin in humans,12 and an evaluation 
of metformin administration in a larger population of 
dogs is recommended to further assess the safety of 
the drug’s use in this species. Long-term administra-
tion of metformin may result in reductions in circulat-
ing vitamin B12 and folate concentrations. Clinicians 
and owners may need to consider supplementation 
with vitamin B12 and folate in cancer patients receiv-
ing long-term metformin treatment.
Results of the present study indicated that a dose of 
10 to 15 mg of metformin/kg administered orally twice 
daily in dogs was well tolerated and resulted in steady-
state serum concentrations less than the upper limit 
of the therapeutic range of metformin in humans (2.5 
mg/L). Data from the present study should help inform 
the selection of dosage regimens and study design of 
randomized clinical trials to investigate the use of met-
formin for treatment and prevention of cancer in dogs.
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Footnotes
a. Metformin-HCl, Sigma Chemical Co, St Louis, Mo.
b. Metformin-HCl tablets, 500 mg, Valeant, Laval, QC, Canada.
c. Indwelling jugular double-lumen sampling catheter, 7F X 
20 cm, MILA International Inc, Florence, Ky.
d. Sorvall ST 8 benchtop centrifuge, ThermoFisher Scientific, 
Burlington, ON, Canada.
e. Allegra 25R centrifuge, Beckman, Indianapolis, Ind.
f. GraphPad Prism 5.0, GraphPad Software Inc, San Diego, 
Calif.
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